secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAge Labs, Inc. (BIOA)
CIK:        0001709941
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064547
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAge Labs Q1 net loss $12.9M; cash $335.1M; BGE-102 Phase 1 data expected 2H25
--------------------------------------------------------------------------------

- Net loss of $12.9M ($0.36 diluted EPS) vs $13.0M loss in Q1 2024; no revenue reported.
- R&D expenses $11.1M up from $9.3M YoY on IND-enabling work for BGE-102.
- G&A expenses $6.8M up from $3.5M YoY driven by stock-based compensation and D&O insurance.
- Cash, equivalents, and marketable securities $335.1M as of March 31, 2025; funds operations through 2029.
- Lead candidate BGE-102 (NLRP3 inhibitor) enters IND-enabling studies; initial Phase 1 data anticipated 2H25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025064547/0000950170-25-064547-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1709941/000095017025064547/bioa-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064547

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer